237 related articles for article (PubMed ID: 27475804)
21. Chordoma.
Ulici V; Hart J
Arch Pathol Lab Med; 2022 Mar; 146(3):386-395. PubMed ID: 34319396
[TBL] [Abstract][Full Text] [Related]
22. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
Vigneron N; Abi Habib J; Van den Eynde BJ
Trends Cancer; 2017 Oct; 3(10):726-741. PubMed ID: 28958390
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
24. [From bench to bedside for new treatment paradigms in chordomas: An update].
Méry B; Rowinski E; Guinand M; Benna M; Bousarsar A; Bosacki C; Vallard A; Magné N
Bull Cancer; 2020 Jan; 107(1):129-135. PubMed ID: 31882268
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
26. Extra-axial chordoma: a clinicopathologic analysis of six cases.
Righi A; Sbaraglia M; Gambarotti M; Cocchi S; Drago G; Casadei R; Picci P; Vanel D; Dei Tos AP
Virchows Arch; 2018 Jun; 472(6):1015-1020. PubMed ID: 29560513
[TBL] [Abstract][Full Text] [Related]
27. Chordoma cutis.
Persichetti G; Walling HW; Rosen L; Cronin T; Ceilley RI
Dermatol Surg; 2007 Dec; 33(12):1520-4. PubMed ID: 18076624
[No Abstract] [Full Text] [Related]
28. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning.
Hug EB; Fitzek MM; Liebsch NJ; Munzenrider JE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):467-76. PubMed ID: 7852108
[TBL] [Abstract][Full Text] [Related]
29. Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable.
Moojen WA; Vleggeert-Lankamp CL; Krol AD; Dijkstra SP
Spine (Phila Pa 1976); 2011 May; 36(10):E656-61. PubMed ID: 21217422
[TBL] [Abstract][Full Text] [Related]
30. Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database.
Gokaslan ZL; Zadnik PL; Sciubba DM; Germscheid N; Goodwin CR; Wolinsky JP; Bettegowda C; Groves ML; Luzzati A; Rhines LD; Fisher CG; Varga PP; Dekutoski MB; Clarke MJ; Fehlings MG; Quraishi NA; Chou D; Reynolds JJ; Williams RP; Kawahara N; Boriani S
J Neurosurg Spine; 2016 Apr; 24(4):644-51. PubMed ID: 26682601
[TBL] [Abstract][Full Text] [Related]
31. Chordoma with increased prolactin levels (pseudoprolactinoma) mimicking pituitary adenoma: a case report with review of the literature.
Kumar P; Kumar P; Singh S; Kumari N; Datta NR
J Cancer Res Ther; 2009; 5(4):309-11. PubMed ID: 20160370
[TBL] [Abstract][Full Text] [Related]
32. En bloc excisions of chordomas in the cervical spine: review of five consecutive cases with more than 4-year follow-up.
Hsieh PC; Gallia GL; Sciubba DM; Bydon A; Marco RA; Rhines L; Wolinsky JP; Gokaslan ZL
Spine (Phila Pa 1976); 2011 Nov; 36(24):E1581-7. PubMed ID: 22048652
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
34. Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma.
Uhl M; Welzel T; Jensen A; Ellerbrock M; Haberer T; Jäkel O; Herfarth K; Debus J
Strahlenther Onkol; 2015 Jul; 191(7):597-603. PubMed ID: 25737378
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
Kim JY; Lee J; Koh JS; Park MJ; Chang UK
J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
[TBL] [Abstract][Full Text] [Related]
37. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
38. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in Sarcoma: Future Horizons.
Burgess M; Gorantla V; Weiss K; Tawbi H
Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
[TBL] [Abstract][Full Text] [Related]
40. Chordoma: the nonsarcoma primary bone tumor.
Chugh R; Tawbi H; Lucas DR; Biermann JS; Schuetze SM; Baker LH
Oncologist; 2007 Nov; 12(11):1344-50. PubMed ID: 18055855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
